| Title |
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, January 2013
|
| DOI | 10.2147/copd.s39018 |
| Pubmed ID | |
| Authors |
Marc L Decramer, Nicola A Hanania, Jan O Lötvall, Barbara P Yawn |
| Abstract |
Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence for the safety of LABAs in COPD, focusing on their effect on exacerbations and deaths. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 8% |
| Argentina | 1 | 8% |
| Switzerland | 1 | 8% |
| Kuwait | 1 | 8% |
| Unknown | 8 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 92% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 3% |
| Finland | 1 | 1% |
| Colombia | 1 | 1% |
| India | 1 | 1% |
| Poland | 1 | 1% |
| Unknown | 65 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 20% |
| Student > Bachelor | 11 | 15% |
| Other | 9 | 13% |
| Student > Master | 9 | 13% |
| Student > Ph. D. Student | 7 | 10% |
| Other | 13 | 18% |
| Unknown | 8 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 52% |
| Agricultural and Biological Sciences | 6 | 8% |
| Nursing and Health Professions | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Other | 7 | 10% |
| Unknown | 11 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2022.
All research outputs
#1,772,155
of 25,373,627 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#124
of 2,577 outputs
Outputs of similar age
#15,925
of 288,991 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#1
of 15 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,991 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.